Engensis, Gene Therapy for CMT1A, Shows Potential in Phase 1 Trial

Engensis, Gene Therapy for CMT1A, Shows Potential in Phase 1 Trial

311632

Engensis, Gene Therapy for CMT1A, Shows Potential in Phase 1 Trial

The investigational gene therapy Engensis (VM202) was generally safe and showed signs of effectiveness at easing sensory neuropathy, or nerve damage, and improving muscle health in people with Charcot-Marie-Tooth disease type 1A (CMT1A), according to data from a Phase 1 clinical trial. A larger Phase 2 trial is being planned to confirm the results of this study, the first gene therapy trial completed in CMT patients, Helixmith, the therapy’s developer, stated in a press release. CMT is…

You must be logged in to read/download the full post.